Predictive factors for response and toxicity after brachytherapy for rectal cancer; results from the HERBERT study.

Abstract

PURPOSE\nThe HERBERT study was a dose-finding feasibility study of a high-dose rate endorectal brachytherapy (HDREBT) boost after external beam radiotherapy (EBRT) in elderly patients with rectal cancer who were unfit for surgery. This analysis evaluates the association of patient, tumor and dosimetric parameters with tumor response and toxicity after HDREBT in definitive radiotherapy for rectal cancer.\n\n\nPATIENTS AND METHODS\nThe HERBERT study included 38 inoperable patients with T2-3N0-1 rectal cancer. Thirteen fractions of 3\u202fGy EBRT were followed by three weekly HDREBT applications of 5-8\u202fGy per fraction. Clinical and dosimetric parameters were tested for correlation with clinical complete response (cCR), sustained partial/complete response (SR), patient reported bowel symptoms, physician reported acute and late proctitis (CTCAE v3) and endoscopically scored toxicity.\n\n\nRESULTS\nThirty-five patients completed treatment and were included in the current analyses. Twenty of 33 evaluable patients achieved a cCR, the median duration of a sustained response was 32\u202fmonths. Tumor volume at diagnosis showed a strong association with clinical complete response (OR 1.15; p\u202f=\u202f0.005). No dose-response correlation was observed in this cohort. Prescribed dose to the brachytherapy CTV (D90) correlated with acute and late physician reported proctitis while CTV volume, CTV width and high dose regions in the CTV (D1cc/D2cc) were associated with endoscopic toxicity at the tumor site.\n\n\nCONCLUSION\nTumor volume is the most important predictive factor for tumor response and a higher dose to the brachytherapy CTV increases the risk of severe clinically and endoscopically observed proctitis after definitive radiotherapy in elderly patients with rectal cancer.